Photo by Tara Winstead on Pexels

OpenAI is working with the Food and Drug Administration (FDA) to explore how artificial intelligence can revolutionize the drug evaluation process. Discussions have centered on projects like ‘cderGPT’, aiming to leverage AI to accelerate and enhance the accuracy of drug approvals. This partnership signifies a growing interest in utilizing advanced AI technologies to streamline regulatory processes within the pharmaceutical industry.